Advertisement
YOU ARE HERE: LAT HomeCollectionsMannkind Corp
IN THE NEWS

Mannkind Corp

FEATURED ARTICLES
BUSINESS
December 9, 2013
The company: MannKind Corp. Headquarters: Valencia Ticker: MNKD Employees: 246 Leadership: Alfred E. Mann, 88, founder, chairman, chief executive 2012 revenue: $35,000 2012 net loss: $170 million Stock price: $5.12 at Friday's close 52-week range: $2.04 to $8.70 P/E ratio: N/A Quarterly dividend: none
ARTICLES BY DATE
BUSINESS
April 2, 2014 | By Stuart Pfeifer
MannKind Corp. shares were up nearly 80% Wednesday after the Valencia company said an FDA advisory panel had backed its inhaled diabetes drug that could replace most insulin injections. The panel voted 13-1 to recommend that the FDA approve the drug, Afrezza, for the treatment of Type 1 diabetes and 14-0 to approve it for the more common Type 2 diabetes. The FDA doesn't have to follow the panel's recommendation, but the panel's nod was considered a key hurdle for the company.
Advertisement
BUSINESS
August 12, 2008 | From Times Wire Services
Biotechnology company MannKind Corp. reported a deeper second-quarter loss as the company faced higher research and development costs. MannKind reported a loss of $79.8 million, or 79 cents a share, compared with a loss of $72 million, or 98 cents, a year earlier. The company recorded no revenue during the quarter. Analysts polled by Thomson Financial expected a loss of 74 cents a share on no revenue. MannKind is developing diabetes and cancer treatments. Its lead product, the Technosphere Insulin System, is in three late-stage clinical trials.
BUSINESS
December 9, 2013
The company: MannKind Corp. Headquarters: Valencia Ticker: MNKD Employees: 246 Leadership: Alfred E. Mann, 88, founder, chairman, chief executive 2012 revenue: $35,000 2012 net loss: $170 million Stock price: $5.12 at Friday's close 52-week range: $2.04 to $8.70 P/E ratio: N/A Quarterly dividend: none
BUSINESS
August 10, 2007 | From Times Wire Services
Biopharmaceutical company MannKind Corp. said its second-quarter loss widened on higher research and development costs. MannKind lost of $72 million, or 98 cents a share, compared with a loss of $54.8 million, or $1.10, a year earlier. The company posted no revenue for the quarter in either year. Analysts polled by Thomson Financial had expected a loss of $1.05 a share on no revenue. Research and development costs rose 36% to $61.5 million.
BUSINESS
May 5, 2009 | Times Wire Reports
Valencia biotechnology company MannKind Corp. posted a smaller loss in the first quarter as expenses fell. The company said it lost $59.4 million, or 58 cents a share, an improvement over its loss of $71.4 million, or 70 cents, a year earlier. It reported no revenue for the quarter, versus $20,000 in revenue a year earlier. Analysts surveyed by Thomson Reuters were expecting a loss of 66 cents a share, with no revenue. The company, which is developing a rapid-acting insulin called Afresa, said it scaled back research-and-development spending by $15.6 million, to $42.9 million, as it shifts from developing the new insulin to getting it ready for commercial use. The company said it submitted a new drug application to the Food and Drug Administration during the quarter.
BUSINESS
December 5, 2008 | Bloomberg News
MannKind Corp., the company staking its future on inhaled insulin, said Thursday that its drug didn't cause adverse lung effects in the last studies for U.S. regulatory approval. MannKind shares rose 18 cents, or 6.2%, to $2.91 after the announcement. The Valencia-based company said its Afresa inhaler met its primary goals in its last two human trials.
BUSINESS
October 3, 2007 | From Times Wire Services
Shares of MannKind Corp., a Valencia-based drug developer that is seeking a partner for its experimental inhaled insulin, posted their biggest gain in almost two months after the firm announced $600 million in new financing. The financing consists of $350 million in added credit and $250 million from the sale of 27 million shares, MannKind said Tuesday. Alfred E.
BUSINESS
June 6, 2007 | Daniel Yi, Times Staff Writer
MannKind Corp. agreed Tuesday to settle a suit brought by a former executive who claimed the Valencia-based pharmaceutical company fired him after he alleged that misleading scientific data had been given to federal regulators. A Los Angeles County Superior Court jury was dismissed after less than three days of deliberations in the wrongful termination case brought by Wayman Wendell Cheatham, MannKind's former vice president of medical and regulatory affairs.
BUSINESS
January 19, 2011 | By Nathan Olivarez-Giles, Los Angeles Times
MannKind Corp. divulged that the Food and Drug Administration has asked for more testing of its key, long-delayed product ? an insulin inhaler for people with diabetes. The Valencia biotech firm said in a statement that Afrezza will require two new clinical trials before U.S. regulators again consider approving the device. Trading of MannKind shares was halted on the Nasdaq exchange before the announcement Wednesday morning. But in after-hours trading, the stock fell more than 40% to $5.25.
BUSINESS
December 8, 2013 | By Ronald D. White
MannKind Corp. in Valencia is attempting to revolutionize the treatment of Type 1 and Type 2 diabetes with its first product: an inhaled form of insulin powder called Afrezza that would eliminate the need for most injections. The company hopes to get federal approval for the Afrezza inhaler system by spring. The company's future and that of its 246 employees are riding on that goal. The dream of an inhaled form of insulin treatment dates from the 1920s, when doctors and researchers worried that diabetes patients wouldn't want to subject themselves to regular injections.
BUSINESS
January 19, 2011 | By Nathan Olivarez-Giles, Los Angeles Times
MannKind Corp. divulged that the Food and Drug Administration has asked for more testing of its key, long-delayed product ? an insulin inhaler for people with diabetes. The Valencia biotech firm said in a statement that Afrezza will require two new clinical trials before U.S. regulators again consider approving the device. Trading of MannKind shares was halted on the Nasdaq exchange before the announcement Wednesday morning. But in after-hours trading, the stock fell more than 40% to $5.25.
BUSINESS
May 5, 2009 | Times Wire Reports
Valencia biotechnology company MannKind Corp. posted a smaller loss in the first quarter as expenses fell. The company said it lost $59.4 million, or 58 cents a share, an improvement over its loss of $71.4 million, or 70 cents, a year earlier. It reported no revenue for the quarter, versus $20,000 in revenue a year earlier. Analysts surveyed by Thomson Reuters were expecting a loss of 66 cents a share, with no revenue. The company, which is developing a rapid-acting insulin called Afresa, said it scaled back research-and-development spending by $15.6 million, to $42.9 million, as it shifts from developing the new insulin to getting it ready for commercial use. The company said it submitted a new drug application to the Food and Drug Administration during the quarter.
BUSINESS
December 5, 2008 | Bloomberg News
MannKind Corp., the company staking its future on inhaled insulin, said Thursday that its drug didn't cause adverse lung effects in the last studies for U.S. regulatory approval. MannKind shares rose 18 cents, or 6.2%, to $2.91 after the announcement. The Valencia-based company said its Afresa inhaler met its primary goals in its last two human trials.
BUSINESS
August 12, 2008 | From Times Wire Services
Biotechnology company MannKind Corp. reported a deeper second-quarter loss as the company faced higher research and development costs. MannKind reported a loss of $79.8 million, or 79 cents a share, compared with a loss of $72 million, or 98 cents, a year earlier. The company recorded no revenue during the quarter. Analysts polled by Thomson Financial expected a loss of 74 cents a share on no revenue. MannKind is developing diabetes and cancer treatments. Its lead product, the Technosphere Insulin System, is in three late-stage clinical trials.
BUSINESS
August 12, 2008 | From Times Wire Services
Calpine Corp., the U.S. power producer that exited bankruptcy protection in January, reported a profit in the second quarter after a year-earlier loss from reorganization costs. Net income was $197 million, or 41 cents a share, compared with a loss of $500 million, or $1.04, San Jose-based Calpine said Monday. Revenue rose 37% to $2.83 billion. The company also named Jack Fusco chief executive. Calpine said Fusco's appointment was effective Sunday.
BUSINESS
April 2, 2014 | By Stuart Pfeifer
MannKind Corp. shares were up nearly 80% Wednesday after the Valencia company said an FDA advisory panel had backed its inhaled diabetes drug that could replace most insulin injections. The panel voted 13-1 to recommend that the FDA approve the drug, Afrezza, for the treatment of Type 1 diabetes and 14-0 to approve it for the more common Type 2 diabetes. The FDA doesn't have to follow the panel's recommendation, but the panel's nod was considered a key hurdle for the company.
BUSINESS
June 1, 2001 | KAREN ROBINSON-JACOBS, TIMES STAFF WRITER
By selling off insulin pump maker MiniMed Inc. for more than $3 billion, biomed mogul Alfred E. Mann cut the cord from the company that was almost synonymous with his name--and that made him a fortune. But to Mann, the separation wasn't traumatic. Even as the ink was drying on the deal to sell MiniMed and its sister firm, Medical Research Group Inc., Mann was plotting the course for two more of his biotech start-ups: one that makes ear implants and the other seeking to develop a cancer vaccine.
BUSINESS
October 3, 2007 | From Times Wire Services
Shares of MannKind Corp., a Valencia-based drug developer that is seeking a partner for its experimental inhaled insulin, posted their biggest gain in almost two months after the firm announced $600 million in new financing. The financing consists of $350 million in added credit and $250 million from the sale of 27 million shares, MannKind said Tuesday. Alfred E.
BUSINESS
August 10, 2007 | From Times Wire Services
Biopharmaceutical company MannKind Corp. said its second-quarter loss widened on higher research and development costs. MannKind lost of $72 million, or 98 cents a share, compared with a loss of $54.8 million, or $1.10, a year earlier. The company posted no revenue for the quarter in either year. Analysts polled by Thomson Financial had expected a loss of $1.05 a share on no revenue. Research and development costs rose 36% to $61.5 million.
Los Angeles Times Articles
|